TrialCPT: pharmacometrics & systems pharmacology2020

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Exposure-Response Analyses of Pivotal ALTA Study.

Neeraj Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.